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To assess the efficacy of the combination of long-acting release (LAR) octreotide and tamoxifen (TMX) for the treatment of
advanced hepatocellular carcinoma (HCC). A total of 109 patients with advanced HCC were randomised to receive octreotide LAR
combined with TMX (n¼ 56) (experimental treatment group) or TMX alone (n¼ 53; control group). The clinical, biological and
tumoural parameters were recorded every 3 months until death. Primary end point was patient survival; secondary end points were
the impact of therapy on tumour response, quality of life and variceal bleeding episodes. Univariate and multivariate analyses were
performed for assessment of specific prognostic factors. The median survival was 3 months (95% CI 1.4–4.6) for the experimental
treatment group and 6 months (CI 95% 2–10) for the control group (P¼ 0.609). There was no difference in terms of a-foetoprotein
(a-FP) decrease, tumour regression, improvement of quality of life and prevention of variceal bleeding between the two groups.
Variables associated with a better survival in the multivariate analysis were: presence of cirrhosis, a-FP levelo400 ng ml1 and Okuda
stage I. The combination of octreotide LAR and TMX does not influence survival, tumour progression or quality of life in patients with
advanced HCC.
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Hepatocellular carcinoma (HCC) is the fifth most common cancer
in the world and the third most common cause of cancer mortality.
Its incidence is increasing worldwide because of the dissemination
of hepatitis B and C virus infection (Van Vlierberghe et al, 2004).
The characteristics of HCC vary geographically. In Asia and sub-
Saharan Africa, HCC occurs mainly in young patients without
cirrhosis, infected early in life by hepatitis B virus. By contrast, in
Western countries, HCC develops in older patients with alcoholic
or hepatitis C-related cirrhosis. Curative therapeutic options
usually consist of transplantation or resection, but for most cases,
palliative therapy is the only option (Llovet and Beaugrand, 2003).
In this setting, best supportive care (BSC) including regulation
of fluid retention with diuretics, abdominal paracentesis and
albumin infusion, and prevention of variceal bleeding with
b-blockers is the only recommendable standard medical therapy.
So far, the majority of medical treatments (apart BSC) assessed in
advanced HCC have shown disappointing results and do not
significantly change the natural course of the disease. The role of
trans-arterial chemo-embolisation in the management of advanced
HCC remains questionable, although there are some studies
reporting survival benefit (Llovet et al, 2002; Lo et al, 2002;
Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire,
2004). Chemotherapeutic options have also been reported as
disappointing and hazardous in the management of HCC due to
the impaired hepatic function and the relative chemoresistance
(Nowak et al, 2004). Owing to its anti-angiogenic and presumably
antiproliferative properties, interferon-a has been used to treat
advanced HCC but failed to be efficient in improving survival
(Llovet et al, 2000).
Regarding hormonal therapy, it clearly appears that flutamide or
LH–RH agonists are not effective (Manesis et al, 1995; Groupe
d’Etude et de Traitement du Carcinome Hepatocellulaire, 2004).
Oestrogen receptors are present in 33% of HCC cases and anti-
oestrogen therapy using tamoxifen (TMX) was widely evaluated in
HCC leading to discrepant results regarding its efficacy (Manesis
et al, 1995; CLIP group, 1998; Mathurin et al, 1998; Liu et al, 2000).
While the former meta-analysis suggested a possible beneficial
role, a recently published meta-analysis reported no significant
benefit with TMX alone and overall, its role as single hormonal
agent in the management of advanced HCC was therefore claimed
to be unbeneficial despite some recent positive results in
subgroups of patients (Barbare et al, 2005; Nowak et al, 2005).
Somatostatin is a hormone with well-proven efficacy for the
treatment of hormone-producing tumours, mainly neuroendocrine
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tumours. The biological effects of somatostatin are mediated
through five G-protein-coupled receptors (SSTR1-5). Similarly to
neuroendocrine tumours, it has been proven that some solid
cancers, including HCC, also express SSTRs (Reubi et al, 1999;
Bla¨ker et al, 2004). These data were recently confirmed by a study
that investigated expression of SSTRs in human HCC using
immunohistochemistry and reverse transcription-PCR (Reynaert
et al, 2004). An in vitro activity of lanreotide, a long-acting
somatostatin analogue, has been demonstrated on hepatoma cell
culture (Hep G2 cell) consisting in decreased cellular proliferation
(S-phase) and increased apoptosis, suggesting thus an antiproli-
ferative effect of somatostatin analogues (Raderer et al, 2000). For
the other somatostatin analogue, octreotide, an antiproliferative
effect on tumour growth in nude mice bearing HCC xenografts has
also been recently demonstrated (Jia et al, 2003). Kouroumalis et al
(1998) reported the first randomised clinical trial assessing
octreotide in advanced HCC and showing a significant impact on
patient survival. Since this study, confirmation data are lacking, as
the results from recent randomised studies comparing octreotide
long-acting release (LAR) vs BSC or placebo failed to show a
survival benefit (Yuen et al, 2002; Barbare et al, 2005; Becker et al,
2007).
In the present study, we aimed to evaluate an hormonal
combined therapy of octreotide and TMX based on the following;
several data have suggested that the deregulation of the insulin-like
growth factor axis (interaction of insulin-growth factor (IGF)-I and
-II with the IGF-1R) plays a pivotal role in hepatocarcinogenesis
and that the inhibition of the IGF-/IGFR-signalling system could
be a valuable and promising approach of HCC treatment; it was
suggested that octreotide is able to inhibit this pathway (Ren et al,
1992; Scharf et al, 2001). Somatostatin analogues have been
reported to decrease IGF-I levels and receptor expression;
furthermore, octreotide has been combined with TMX in
preclinical and clinical settings and in a rat model, this
combination was able to decrease IGF-I serum levels and hepatic
gene expression more profoundly than either agent administered
alone (Huynh and Pollak, 1994; Weckbecker et al, 1994; Pollak,
1996; Bontenbal et al, 1998). In patients with breast cancer, such a
combination has yielded a more profound suppression of IGF-I
level, which was however not translated into a clinical benefit
(Ingle et al, 1999; Helle et al, 2005). On the basis of this possible
synergy between two hormonal therapies, we designed this
prospective randomised multicentre study aiming to evaluate the
efficacy of the doublet octreotideþTMX for the treatment of
advanced HCC, not amenable to surgery or local therapy. In the
control arm, we chose to give TMX since its role was not yet
definitely clarified at the start of the current study in 2001, the aim
of the study being to demonstrate an advantage of administering
two hormonal therapies on a single one. Primary end point was
survival; secondary end points were the impact of therapy on
tumour response, quality of life and also on the incidence of
variceal bleeding, as somatostatin analogues are able to decrease
portal pressure (de Franchis, 2000; Spahr et al, 2007).
PATIENTS AND METHODS
Study design and admission criteria
Between March 2001 and March 2005, 18 Belgian Hospital Centers
included patients with advanced HCC in the study. Written
informed consent was obtained from each patient before entering
the study, and the study protocol was approved by the ethics
committees of all participating centres.
Patients were eligible to be admitted to the study if they fulfilled
the following criteria: (1) diagnosis of HCC established by
histology or by the coincidental findings of two imaging
techniques showing a nodule of 42 cm with arterial hypervascu-
larisation, or by a single positive imaging technique associated
with a-foetoprotein (a-FP) level of 4400 ng ml1 (according to the
Barcelona-2000 EASL conference; Bruix et al, 2001) (2) advanced
disease not amenable to curative resection, liver transplant or
locoregional treatment after multidisciplinary conference (patients
with recurrence after surgery/transplantation were eligible), (3) age
above 18 years, (4) Karnofsky performance status (KPS) X60, (5)
life expectancy of at least 2 months.
Exclusion criteria were: (1) history of other malignancy, (2)
unstable serious coexisting medical condition, (3) known cerebral
metastasis, (4) Child –Pugh score 410, (5) platelet count
o20 000 mm3.
Baseline assessment included a complete physical examination,
determination of KPS, laboratory tests and tumour characteristics
assessed by imaging and Okuda score (Okuda et al, 1985). The
laboratory tests consisted of complete blood count, prothrombin
time, liver biochemistry, serum albumin level (to determine the
Child–Pugh score) and a-FP level.
Interventions and randomisation
Patients were stratified by centres and Child– Pugh score, and were
assigned through a computer-generated randomisation list to
the experimental treatment group (octreotideþTMX) or to the
control group (TMX alone) in 1 : 1 ratio. An intramuscular
injection of 30 mg octreotide LAR was administered once monthly
in the experimental treatment group, and a daily dose of 20 mg
TMX was administered orally in both groups. Best supportive care
including b-blockers, diuretics, paracentesis and albumin infusion
was allowed in both arms.
Follow-up and end points
Patients were followed up monthly until death. All the clinical
(included KPS) and biological parameters and all drugs adminis-
tered were recorded each month. Any treatment-related adverse
events was monitored and noted. In addition, the number of
variceal bleeding episodes was recorded in each patient from both
groups.
The tumour response was assessed using the serum a-FP level
and the sum of longest diameter of the target lesions measured
at baseline, 3 and 12 months according to the RECIST criteria
(Duffaud and Therasse, 2000).
Radiological complete response was defined as complete
disappearance of the tumour; partial response as at least a 30%
decrease in the diameter of the target lesion without simultaneous
increase in the size of any other lesion or appearance of new lesion;
progressive disease as at least a 20% increase in the diameter of the
target lesion or emergence of new lesions; stable disease for the
intermediary cases.
Similarly, an increase or a decrease of the a-FP level was defined
by a variation of more than 25% compared to the baseline value.
Survival was calculated from the date of randomisation to the
date of last follow-up or death.
The primary end point of the study was the effect of treatment
on survival; secondary end points were the effects on tumour
progression, quality of life and variceal bleeding.
Sample size calculation and statistical analysis
On the basis of the published data, 1-year survival in the control
group ranges from 10 to 30%. Expecting a 30% 1-year survival rate
in the control group, aiming to achieve a 50% 1-year survival rate
in the experimental treatment group, and requiring a level of
statistical significance of 0.05 and a power of 0.9, 90 patients were
planned to be included in the study (45 in each arm).
Continuous variables were expressed in median with minimal
and maximal value, and in percentages for discretes variables. The
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Mann– Whitney test was used to compare continuous variables
and the w2 test or Fischer’s exact test for the discrete variables.
Survival curves were drawn according to the Kaplan–Meier
method and compared by the log-rank test. Survival was analysed
on an intention-to-treat (ITT) basis; an exploratory subgroup
analysis was also performed only considering the patients with
treatment exposure X2 months.
A stratified Cox proportional hazard regression model was used
for multivariate analysis, using age, gender, treatment by
octreotide LAR, presence of cirrhosis, Child–Pugh stage, a-FP
level and Okuda stage as covariates, to determine independent
prognostics factors possibly affecting survival.
P-values o0.05 were considered as statistically significant. Data
analysis was carried out with the computer programme SPSS
version 11 (SPSS Inc., Chicago, IL, USA).
RESULTS
Baseline characteristics
One-hundred and fourteen patients were included between March
2001 and March 2005. Three patients were found ineligible after
randomisation because a different tumour was diagnosed: one with
prostatic adenocarcinoma, one with colonic adenocarcinoma and
one with peritoneal carcinomatosis from an adenocarcinoma.
Two patients decided to discontinue the study a few days after
randomisation without receiving any treatment (Figure 1).
One-hundred and nine patients were thus analysed: 56 were
assigned to the experimental treatment group and 53 to the control
group. Groups were comparable with respect to age, gender,
presence of cirrhosis, Child –Pugh score, aetiology of hepatopathy,
Okuda classification, KPS, a-FP level and size of target lesion
(Table 1).
The median follow-up in this study was 3 months (range, 0.1–
31), and the median number of octreotide LAR injections was 2
(range, 1– 31) in the octreotide group. All patients continued to
take TMX until death.
Adverse events and reasons of study discontinuation
Four patients discontinued the study for drug-related toxicity.
Only one patient in the experimental treatment group stopped the
treatment for diarrhoea (Table 2).
Survival data
In ITT analysis, the median survival was 3 months (95% CI 1.4–
4.5) for the experimental treatment group and 6 months (95% CI
2–10) for the control group (P¼ 0.609) (Figure 2). Among the 70
patients who had a treatment exposure of X2 months, there was
no difference in survival between the two groups (8 months (95%
CI 5.6–10.4) for the experimental treatment group and 6 months
(95% CI 4.1– 7.9) for the control group (P¼ 0.930).
Registered, n = 114
 Non-eligible, n = 3  
Colic cancer, n = 1
      Concomittant prostatic cancer, n = 1 
      Metastatic abdominal nodes, n = 1 
Eligible, n = 111
  Nonrandomly assigned, n = 2 
Patient’s refusal, n = 2
Randomly assigned, n = 109
Experimental treatment group, n = 56 
Octreotide LAR 30 mg i.m. monthly 
Daily dose of 20 mg tamoxifen 
Control group, n = 53
Daily dose of 20 mg tamoxifen alone 
Liver transplantation n = 1 
Lost to follow-up n = 4 
Stop for adverse event  n = 1 
Intention-to-treat analysis n = 56
Died n = 55
Alive at time of analysis n = 1 
Alive at 2 months n = 33 
Transarterial chemoembolisation
Lost to follow-up n = 2 
n = 1
Stop for adverse event  n = 1 
Intention-to-treat analysis n = 53
Died n = 52
Alive at time of analysis n = 1 
Alive at 2 months n = 37 
Figure 1 Participant flow chart.
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Tumour response, quality of life and variceal bleeding
Tumour response at 3 months was assessed by the evolution of
target lesion’s diameter and a-FP level. No significant difference
was observed between the two groups (Table 3).
Evolution of KPS at 3 months was also studied to evaluate a
possible impact of octreotide on quality of life. The median KPS
after 3 months on therapy was similar: 80 in each group (95% CI
40–100 octreotide group, 30–100 for control group; P¼ 0.769;
Table 3).
In addition, there was no difference in terms of variceal bleeding
episodes between the two groups (0 bleeding in the experimental
treatment group vs 2 bleeding in the control group; P¼ 0.477).
Prognostic factors of survival
The univariate analysis showed a significant relation between
survival and Okuda stage, a-FP level, Child–Pugh score and
absence of underlying cirrhosis (Table 4).
In multivariate analysis, absence of underlying cirrhosis, a-FP
level and Okuda stage were revealed as independent prognostic
factors affecting survival (Table 5). Patients with a HCC in a non-
cirrhotic liver deceased significantly earlier than patients with
cirrhosis: relative risk (RR)¼ 2.002 (CI 95% 1.044– 4.073).
Similarly, a-FP level4400 ng ml1 and Okuda stage III have
negative impact on overall survival: RR¼ 2.810 (95% CI 1.469 –
5.374) and RR¼ 3.014 (95% CI 1.118 –8.126) respectively.
Table 1 Baseline characteristics
Experimental
treatment
group (n¼ 56)
Control
group (n¼ 53) P
Median age (years) (range) 64.5 (39–84) 68 (38–83) 0.202
Male gender (%) 78.6 83 0.366
Histology proven (%) 55.4 71.7 0.058
Cirrhosis (%) 82 79.2 0.298
Child (%)
A 55.4 71.7 0.208
B 39.3 24.5
C 5.4 3.8
Aetiology (%)
OH 52.4 40.5 0.742
HBV 9.5 10.8
HCV 33.3 40.5
Other 4.8 8.1
Median KPS (range) 80 (60–100) 80 (60–100) 0.373
Median a-foetoprotein
(ng ml1) (range)
265 (1.6–498000) 98.1 (0–1135659) 0.378
Median diameter of target
lesion (mm) (range)a
55 (3–160) 56 (4.1–280) 0.823
Okuda stage (%)
1 36.4 41.3 0.565
2 50.9 52.2
3 12.7 6.5
HBV¼ hepatitis B virus; HCV¼ hepatitis C virus; KPS¼ Karnofsky performance
status; OH¼ ethanol. aMeasurable for 100 patients (51: experimental treatment
group, 49: control group).
Table 2 Reasons for study discontinuation and study treatment-related
adverse events
Causes
Experimental treatment
group (n¼ 56)
Control group
(n¼ 53)
General status degradation 6 5
Non-compliance/LFU 6 3
Adverse event X grade 3 1 3
Diarrhoea grade 3 1
Nausea grade 3 1
Flush 1
Gynaecomastia 1
Other treatments 2 2
Transplantation/surgery 2
TACE 1
PEI 1
LFU¼ lost of follow-up; PEI¼ percutaneous ethanol injection; TACE¼ transarterial
chemoembolisation.
35302520151050
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P = 0.609
Octreotide group
Control group
Figure 2 Survival curves for experimental treatment (octreoti-
deþTMX) and control (TMX) groups for 109 patients (ITT analysis).
Cumulative survival probability is given on the y axis and time in months is
given on the x axis. Log-rank test showed no significant differences
between survival for the experimental treatment group (solid line, n¼ 56)
and the control group (dashed line, n¼ 53).
Table 3 Assessment of tumour response and quality of life at 3 months
Parameters
Experimental treatment
group (n¼ 25)
Control group
(n¼ 30) P
Radiological responsea
PR(%) 5 3.7 0.872
Progression (%) 65 59.3
Stable (%) 30 37
a-Foetoprotein levelb
Decrease 425% (%) 27.8 10.7 0.282
Stable (%) 16.7 28.6
Increase 425% (%) 55.6 60.7
Median KPS 80 80 0.769
aData available for 20 patients in the experimental treatment group and 26 in the
control group. bData available for 18 patients in the experimental treatment group
and 28 in the control group. PR¼ partial response; KPS¼ Karnofsky performance
status.
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DISCUSSION
Most of the patients with HCC are not eligible for surgical or
locoregional procedures (trans-arterial chemo-embolisation,
radiofrequency ablation, percutaneous ethanol injection). For
these advanced cases, various systemic treatments have been
proposed, poorly or not impacting on survival (Bruix et al, 2001).
Systemic chemotherapy and immunotherapy (IFN-a) have only
marginal activity and are poorly tolerated in cirrhotic patients
(Llovet et al, 2000; Nowak et al, 2004).
Since the Kouroumali’s publication on the impact of somato-
statin analogues in advanced HCC, results of the three subsequent
randomised controlled trials assessing octreotide LAR were
disappointing, reporting only very poor survival data and benefit
and infirming the initial study (Table 6).
The first trial, published in 1998 by Kouroumalis has shown a
significant improvement on survival and on quality of life in 28
patients with advanced HCC treated with subcutaneous octreotide
compared with the control group (n¼ 30); afterwards, three other
randomised studies using octreotide LAR did not confirm these
results (Yuen et al, 2002; Barbare et al, 2005; Becker et al, 2007).
The first study using octreotide LAR, reported by Yuen et al
(2002), was controversial and criticable because the selected
patients had a very short survival (1.9 months in the control group
(n¼ 35) vs 2 months in the octreotide group (n¼ 35)), probably
due to a high proportion of advanced HCC with CLIP score 44
and a poor treatment exposure. In this setting, it was impossible to
detect any benefit for octreotide treatment. The two other negative
randomised studies with octreotide LAR reported by Barbare et al
(2005) and Becker et al (2007) were more relevant because they
used a placebo control arm; the tumour characteristics were well
described and the patients’ cohorts were larger. Survival in the
two groups was longer but not significantly different. Several
additional smaller non-randomised studies were also published
reporting conflicting or inconclusive results that do not help us
very much (Raderer et al, 2000; Dimitroulopoulos et al, 2002; Rabe
et al, 2002; Samonakis et al, 2002).
Our study conclusions are on the same line as the others
mentioned above, reporting similar data and proportion of
advanced disease (18% of Okuda III) that German Study did
(Becker et al, 2007).
However, when we designed the study in 2001, the real impact of
blocking oestrogen receptors by TMX in HCC was still con-
troversial and the unique available meta-analysis suggested at
this time a small advantage for this therapy (Mathurin et al, 1998).
On the other hand, we found a rationale for using a synergistic
combination of two hormonal therapies as it was shown in
preclinical studies and metastatic breast cancer (Huynh and
Pollak, 1994; Ingle et al, 1999; Helle et al, 2005). Furthermore, it is
now clear that IGF-/IGFR-signalling pathway plays a pivotal role
in hepatocarcinogenesis (Scharf et al, 2001). Octreotide is a good
candidate for inhibiting the IGF axis, and a synergistic effect with
TMX has been demonstrated in animal models (Huynh and Pollak,
1994). This is why we preferentially choose to compare this
experimental doublet therapy to a control one based on a single
anti-hormonal agent, in the absence of other standard and effective
therapeutic options. As this combination was not able to
demonstrate any survival benefit in the experimental group, we
did not evaluate the modulation of the IGF axis in the present
study; however, we strongly believe that more potent IGF-R
inhibition using new targeted agents, such as NVP-AEW541
deserves further exploration in HCC (Hopfner et al, 2006).
Interestingly, we observed no survival benefit using this doublet,
even in the patients exposed to the drugs more than 2 months.
Table 4 Variables associated with better survival in univariate analysis
Baseline parameters Median survival 95% CI P
Age (years)
p70 4.5 1.5–7.5 0.250
470 4.0 1.8–6.2
Gender
Male 6.0 3.1–8.9 0.139
Female 2.0 1.0–3.0
Treatment
Experimental (octreotide+TMX) 3.0 0.9–5.1 0.574
Control (TMX alone) 6.0 1.9–10.1
Cirrhosis
Yes 6.0 2.8–9.2 0.049
No 3.0 0.6–5.4
Child
A 6.0 4.3–7.7 0.031
B 1.5 0.7–2.3
C 2.5 0.1–4.9
a-Foetoprotein (ng ml1)
o400 6.0 2.7–9.3 0.036
X400 2.0 1.1–2.9
Okuda stage
I 7.0 1.8–12.2 0.01
II 3.0 1.5–4.5
III 1.5 1.0–2.0
Table 5 Variables associated with a better survival in multivariate analysis
RR 95% CI P
Cirrhosis
Yes 1
No 2.002 1.044–4.073 0.037
a-foetoprotein
o400 ng ml1 1
X400 ng ml1 2.810 1.469–5.374 0.002
Okuda stage
I 1
II 1.154 0.550–2.422 0.705
III 3.014 1.118–8.126 0.029
95% CI¼ 95% confidence interval; RR¼ relative risk. Bold values are statistically
significant.
Table 6 Randomised trials evaluating the efficacy of octreotide in HCC
Authors Treatment n
Median survival
(month) P
Kouroumalis et al
(1998)
Octreotide 28 13 0.002
BSC 30 4
Yuen et al (2002) Octreotide LAR 35 1.9 NS
BSC 35 2
Barbare et al (2005) Octreotide LAR 133 6.77 NS
(Abstract) Placebo 131 7.86
Becker et al (2007) Octreotide LAR 60 4.7 NS
Placebo 59 5.3
Present study Octreotide
LAR+TMX
57 3.0 NS
TMX 59 5.3
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This is a remarkable finding while in the previous Korean study, a
major criticism was that the therapeutic intervention was very
short and survival extremely limited (Yuen et al, 2002).
No difference was observed between the two groups in terms of
radiological tumour response, decrease in a-FP levels and impact
on quality of life. Moreover, we failed to observe an effect of
preventing variceal bleeding, despite the hypothesis of a potential
reduction in hepatic venous pressure gradient induced by
octreotide, recently confirmed by a randomised controlled study
comparing octreotide LAR to placebo (Spahr et al, 2007).
In the univariate analysis, we identified the following known
factors of poor prognostic: a-FP X400 ng ml1, Okuda stage III
and the severity of cirrhosis assessed by the Child–Pugh score, as
observed in the German study (Becker et al, 2007). In the
multivariate analysis, a-FP level and the Okuda stage persisted as
independent variables. More surprisingly, the absence of cirrhosis
emerged as a negative predictor in univariate and multivariate
analysis. This could be explained by the fact that the mechanisms
of hepatocarcinogenesis and the characteristics of the tumour in
non-cirrhotic liver are different and could confer a more
aggressive behaviour of the HCC. Another explanation could be
a selection bias because we only assessed the tumour character-
istics by a-FP level and the Okuda stage without evaluation of
tumour morphology, vascular invasion and the existence of distant
metastasis. It is therefore possible that, in non-cirrhotic patients,
HCC was diagnosed at a more advanced stage with portal invasion
or secondary localisation, contrasting with cirrhotic patients who
benefit from screening programmes and earlier diagnosis.
Several arguments could be mentioned to explain the negative
results of the study. First, an imbalance regarding vascular
involvement and extra-hepatic metastases could exist between
the experimental treatment and the control groups, as we did not
assess these parameters in our trial. Nevertheless, in the multi-
centre French and German studies (Barbare et al, 2005; Becker
et al, 2007), these two parameters were included and, clearly, this
did not result in a benefit for octreotide LAR in the reported
analysis. Secondly, somatostatin acts through five G-protein-
coupled receptors (SSTR 1 –5). These SSTRs have been identified
in various solid tumours including human HCC. It seems that only
40% of HCC expressed SSTRs and that the expression pattern and
the expression levels of SSTRs are heterogeneous in HCCs and are
independent of the stage, the histological type of the tumour or the
underlying liver disease.
SSTR5 is the most important subtype of receptor expressed by
HCC, followed by SSTR3, SSTR1 and SSTR2. Pharmacological
studies have shown that the long-acting somatostatin analogues
have high affinity for SSTR2, an intermediate affinity for SSTR5
and SSTR3, and almost no affinity for SSTR1 and SSTR4 (affinity
rank order: SSTR24SSTR54SSTR3) (Reubi et al, 1999; Bla¨ker
et al, 2004; Reynaert et al, 2004).
Animal models and in vitro studies have shown that octreotide
is a potent anti-angiogenic factor. This effect is probably mediated
by SSTR3 and is dose-dependent (Jia et al, 2003). It is therefore
possible that the positive results observed in the Greek study using
short-acting somatostatin analogues may be explained, at least in
part, by its suppressive effects on angiogenesis and therefore on
tumour blood supply. This effect may not be observed in studies
using long-acting analogues due to pharmacological reasons.
In conclusion, our results do not support a synergistic effect of
the combination of octreotide and TMX as suggested in breast
cancers and reinforce the lack of efficacy for hormonal therapy in
HCC, even for combination.
In this study, octreotide LAR associated with TMX did not
provide any benefit in terms of survival, tumour response or
quality of life compared with TMX alone in patients with advanced
HCC. Hence, octreotide LAR is not recommendable for this
indication, outside of clinical trials including patients with
advanced HCC specifically expressing SSTRs. Further studies are
therefore mandatory to detect subgroups of patients with HCC that
could benefit from treatment with somatostatin analogues.
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